MAXCYTE, INC.

For the period ended Dec 31, 2025. Filed Mar 25, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 25, 2026

MXCT$1.13-13.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

Consolidated Statements of Cash Flows

(in thousands)


· · Year Ended December 31, ·
· · 2025 · · 2024 ·
Cash flows from operating activities: · · · ·
Net loss	$(44,630)	$(41,055)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,340	4,315
Goodwill impairment	3,554	—
Lease right-of-use asset amortization	802	475
Net book value of consigned equipment sold	83	63
Loss on disposal of property and equipment	287	861
Stock-based compensation	9,213	13,083
Credit loss expense (recovery)	35	(130)
Change in excess/obsolete inventory reserve	676	1,771
Amortization of discounts on investments	(2,646)	(6,242)

Changes in operating assets and liabilities, net of effects of acquisition:
Accounts receivable	1,148	1,226
Inventory	575	1,362
Prepaid expense and other current assets	(531)	293
Other assets	(724)	(1,213)
Accounts payable, accrued expenses and other	(3,721)	(1,883)
Operating lease liability	(1,157)	(709)
Deferred revenue	(1,678)	182
Other liabilities	(36)	(9)
Net cash used in operating activities	(34,410)	(27,610)

Cash flows from investing activities:
Purchases of investments	(126,286)	(150,857)
Maturities of investments	155,762	159,440
Purchases of property and equipment	(1,768)	(1,651)
Acquisition of business, net of cash acquired of $541	(1,773)	—
Net cash provided by investing activities	25,935	6,932

Cash flows from financing activities:
Proceeds from exercise of stock options	432	1,597
Proceeds from issuance of common stock under employee stock purchase plan	224	459
Net cash provided by financing activities	656	2,056
Net decrease in cash and cash equivalents	(7,819)	(18,622)
Cash and cash equivalents, beginning of year	27,884	46,506
Cash and cash equivalents, end of year	$20,065	$27,884

Supplemental disclosure of non-cash investing and financing activities:
Property and equipment purchases included in accounts payable and accrued expenses	$33	$97
Right-of-use assets obtain in business combination by assumption of lease liabilities	$956	$—

MaxCyte, Inc.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.